How does Spikevax LP.8.1 (mRNA-1273.251) stimulate an immune response against SARS-CoV-2?

After intramuscular injection, Spikevax LP.8.1 (mRNA-1273.251) delivers lipid-encapsulated mRNA into cells, which transiently produce prefusion-stabilised SARS-CoV-2 spike protein recognised as foreign, triggering T-cell and B-cell responses and neutralising antibodies that may contribute to protection against COVID-19.